From the ‡Department of Microbiology, Immunology and Pathology.
§Proteomics and Metabolomics Facility, Colorado State University, Fort Collins, CO.
Mol Cell Proteomics. 2018 Sep;17(9):1685-1701. doi: 10.1074/mcp.RA118.000821. Epub 2018 May 29.
Tuberculosis (TB) continues to be an important public health threat worldwide, due in part to drug resistant () strains. The United States recently reported a shortage of isoniazid (INH), which could drive higher INH resistance rates. Changes in the proteome before and after acquisition of INH resistance in a clean genetic background remain understudied and may elucidate alternate drug targets. Here, we focused on clonal strains to characterize the consequences of INH resistance on mycobacterial metabolism. Proteomic analysis was conducted by liquid-chromatography tandem mass spectrometry (LC-MS/MS) of cellular and secreted fractions, followed by a normalized spectral counting (NSAF) analysis (data are available via ProteomeXchange with identifier PXD009549). Two different clonal pairs representing a specific genetic lineage (one clinical and one generated in the laboratory) but sharing a mutation associated with INH resistance, were used in our analysis. Overall, we found 26 proteins with altered abundances after acquisition of INH resistance across both genetic lineages studied. These proteins were involved in ATP synthesis, lipid metabolism, regulatory events, and virulence, detoxification, and adaptation processes. Proteomic findings were validated by Western blotting analyses whenever possible. Mycolic acid (MA) analysis through LC/MS in the clonal pairs did not reveal a common trend in the alteration of these fatty acids across both INHr strains but revealed a significant reduction in levels of the two more abundant α-MA features in the clinical INHr strain. Interestingly, the clinical clonal pair demonstrated more variation in the abundance of the proteins involved in the FAS II pathway. Together, the proteomic and lipidomic data highlight the identification of potential drug targets such as alternative lipid biosynthetic pathways that may be exploited to combat clinically relevant INHr strains.
结核病(TB)仍然是全球重要的公共卫生威胁,部分原因是耐药菌株的出现。美国最近报告异烟肼(INH)短缺,这可能导致 INH 耐药率上升。在清洁遗传背景下获得 INH 耐药前后蛋白质组的变化仍研究不足,可能阐明替代药物靶点。在这里,我们专注于克隆株,以表征 INH 耐药对分枝杆菌代谢的影响。通过细胞和分泌部分的液相色谱串联质谱(LC-MS/MS)进行蛋白质组分析,随后进行归一化光谱计数(NSAF)分析(通过 ProteomeXchange 以标识符 PXD009549 提供数据)。我们的分析使用了两个不同的克隆对,代表了一个特定的遗传谱系(一个临床和一个在实验室中产生),但共享与 INH 耐药相关的突变。总体而言,我们发现了 26 个在获得 INH 耐药后丰度发生改变的蛋白质,跨越了所研究的两个遗传谱系。这些蛋白质参与 ATP 合成、脂质代谢、调节事件以及毒力、解毒和适应过程。尽可能通过 Western blot 分析验证蛋白质组学发现。通过 LC/MS 在克隆对中进行的分枝酸(MA)分析并未显示两种 INHr 菌株中这些脂肪酸改变的共同趋势,但在临床 INHr 菌株中,两种更丰富的α-MA 特征的水平显著降低。有趣的是,临床克隆对参与 FAS II 途径的蛋白质丰度变化更大。总之,蛋白质组学和脂质组学数据突出了鉴定潜在药物靶点的重要性,例如替代脂质生物合成途径,这可能被用于对抗临床相关的 INHr 菌株。